Quidel Corporation (QDEL)
|Net Income (ttm)||899.56M|
|Day's Range||128.07 - 135.84|
|52-Week Range||103.31 - 288.70|
|Price Target||135.50 (+5.7%)|
|Est. Earnings Date||Oct 28, 2021|
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables... [Read more...]
In 2020, QDEL's revenue was $1.66 billion, an increase of 210.66% compared to the previous year's $534.89 million. Earnings were $810.29 million, an increase of 1,011.18%.Financial Statements
According to 5 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price forecast is 135.50, which is an increase of 5.66% from the latest price.
COVID-19 testing volumes are up again.
Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.
Quidel Corporation (NASDAQ: QDEL) announced preliminary estimates for its Q3 revenues are expected to rise between 6% and 7% Y/Y on COVID-19 assay sales. Related: Quidel Stock Falls As Q2 Earnings Mis...
Thursday's gains could be just the beginning.
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced tod...
These could be good hedges to help offset the pandemic-related risks.
A few months back we discussed that Quidel stock looks undervalued at levels of around $108, based on the testing demand and the company's future growth prospects. QDEL stock has since rallied 36% to $1...
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.
Demand for its COVID tests are rising with cases.
Quidel Corporation's (NASDAQ: QDEL) non-prescription QuickVue At-Home OTC COVID-19 Test will be available next week at CVS Pharmacy locations across the U.S. and online at cvs.com. CVS Pharmacy is a par...
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced in ...
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leadi...
SAN DIEGO--(BUSINESS WIRE)-- #Fishing--LivLyme Foundation Founder Olivia Goodreau to discuss her journey with Lyme and the importance of early testing as part of webinar to be held Aug. 19
The company's Q2 headline numbers were nowhere near analyst estimates.
Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.
Quidel Corporation (NASDAQ: QDEL) reported after the close of the market Thursday that its second-quarter revenues fell 12% Y/Y to $176.6 million, below the consensus of $194.5 million. The decline is a...
Quidel (QDEL) delivered earnings and revenue surprises of -37.50% and 1.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financia...
Quidel (QDEL) is likely to have registered solid product sales during Q2 which are likely to have driven its overall top line.
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company's next earnings report could be another disappointment.
Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Be...
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announc...